Evolution of the Average Target: Virbac

Data source: Virbac(VIRP)

Evolution of the Target Price: Virbac

Data source: Virbac(VIRP)

Changes in Analyst Recommendations: Virbac

Data source: Virbac(VIRP)
2154f136308.asS7I5pGrSYn6_JNzp-qW9bvRo8Rtwvzbbsthb9tVys.R57BUPcR4RBGpqQrvenDDreYMfZc_0a1D4NjwoYiPl4si_hlqiXOdn3Zpw~910fd6f820b7b2977088fdcdc7576331
20/08 Cancer vaccines finally garner the spotlight Alphavalue
21/07 Virbac: Impressive execution in Q2; we smell a guidance upgrade in Q3 Alphavalue
14/07 Where would AI lead Pharma in the long run? Alphavalue
11/05 Virbac continues decline despite positive recommendation Zonebourse
17/04 Virbac: 2026 starts on strong footing Alphavalue
19/03 Stifel sees Virbac as undervalued, sets 440 euro price target Zonebourse
18/03 Virbac in the green following results and outlook Zonebourse
20/01 Virbac beats 2025 targets, lifts 2026 outlook Alphavalue
20/01 Stifel Raises Price Target on Virbac Zonebourse
20/01 Virbac Significantly Outperforms the Market with Annual Revenues and 2026 Targets Zonebourse
17/25/17 Virbac: Q3 crushed doubts about execution ability Alphavalue
17/25/17 The day the Fed resumed its rate cuts Zonebourse
15/25/15 Virbac: Oddo BHF remains positive despite H1 results Zonebourse
17/25/17 Virbac: A healthy Q2 impresses the markets Alphavalue
03/25/03 Oddo BHF Upgrades Virbac to Outperform, Boosts PT MT
03/25/03 Virbac: Oddo BHF upgrades stock Zonebourse
17/25/17 Virbac: brokers' advice following quarterly results Zonebourse
16/25/16 Virbac: Stifel remains bullish after quarterly results Zonebourse
16/25/16 Virbac: Decent Q1; Clarity on US tariff exposure was a key takeaway Alphavalue
16/25/16 Virbac: Stifel still buying after Q1 results Zonebourse
17/25/17 Virbac: Oddo BHF remains 'neutral', confirms its target Zonebourse
17/25/17 Virbac: 2024 profitability somewhat exceeded expectations; stock re-rating underway Alphavalue
17/25/17 Virbac: Stifel raises its recommendation Zonebourse
17/25/17 Virbac: 2024 top-line goals met; uninspiring 2025 outlook could be raised later Alphavalue
17/25/17 Oddo BHF Downgrades Virbac to Neutral, Cuts PT MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+26.63%
+27.41%
+49.07%
+31.17%
+17.24%
+7.54%
- +15.03%
+12.27%
- +27.84%
Average +23.80%
Weighted average by Cap. +27.03%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
314.00EUR
Average target price
411.88EUR
Spread / Average Target
+31.17%
High Price Target
440.00EUR
Spread / Highest target
+40.13%
Low Price Target
360.00EUR
Spread / Lowest Target
+14.65%

Analyst Consensus Detail

Consensus revision (last 18 months)

Trader
Investor
Global
Quality
ESG MSCI
AA
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!